Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy

Journal of Medical Virology

Volumn 84, Issue 6, 2012, Pages 885-889

  Routy, J P ^a   Boulassel, M R ^a   Nicolette, C A ^b   Jacobson, J M ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Argos Therapeutics Inc   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antiretroviral treatment interruption; Dendritic cells; HIV; Immunotherapy; SMART

Indexed keywords

ANTIVIRUS AGENT; IMMUNOMODULATING AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CELL THERAPY; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; TREATMENT PLANNING; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADULT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; WITHHOLDING TREATMENT;

EID: 84859783970     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23297     Document Type: Article

References (12)

1. Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD, INSIGHT SMART Study Group. 2011. Changes in inflammatory and coagulation biomarkers: A randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 56: 36- 43.
2. Hirschel B, Flanigan T. 2009. Is it smart to continue to study treatment interruptions? AIDS 23: 757- 759.
3. Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ, Jr., Coombs RW, Wang R, Fox L, Johnson VA, Cu-Uvin S, Cohn SE, Mildvan D, O'Neill D, Janik J, Purdue L, O'Connor DK, Vita CD, Frank I, National Institute of Allergy and Infectious Diseases-AIDS Clinical Trials Group 5068 Protocol Team. 2006. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: The results of AIDS Clinical Trials Group 5068. J Infect Dis 194: 623- 632.
4. Kaufmann GR, Elzi L, Weber R, Furrer H, Giulieri S, Vernazza P, Bernasconi E, Hirschel B, Battegay M, Swiss HIV Cohort Study. 2011. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 25: 441- 451.
5. Kinloch-de Loes S. 2004. Role of therapeutic vaccines in the control of HIV-1. J Antimicrob Chemother 53: 562- 566.
6. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN, INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. 2009. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 200: 973- 983.
7. Routy JP, Boulassel MR, Mona L, Sylvie V, Cécile T, Jonathan A, John G, Jean-Guy B, Fiona S, Renu J, Don H, Irina T, Charles N, Sékaly RP. 2009. Safety and viral load changes in HIV-1 infected subjects treated with autologous dendritic immune therapy following ART discontinuation (CTN#239). Retrovirology 6: O29.
8. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Finke L, Sékaly RP. 2010. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 134: 140- 147.
9. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC, INSIGHT SMART Study Group. 2011. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780- 790.
10. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C, 2006. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283- 2296.
11. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN, 2008. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 197: 1145- 1155.
12. Tcherepanova I, Harris J, Starr A, Cleveland J, Ketteringham H, Calderhead D, Horvatinovich J, Healey D, Nicolette CA. 2008. Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection. PLoS ONE 3: e1489.